Normal Pressure Hydrocephalus: The Daily PANCE Blueprint

Normal Pressure Hydrocephalus: The Daily PANCE Blueprint

A 74-year-old man is evaluated for 8 months of progressive difficulty walking. He describes his feet as feeling stuck to the floor, takes short shuffling steps with a wide base, and has had several falls. Over the same period he has developed urinary urgency and incontinence and mild forgetfulness. There is no tremor and no rigidity. MRI shows ventricular enlargement out of proportion to the degree of cortical atrophy. Lumbar puncture shows a normal opening pressure and normal cerebrospinal fluid studies, and his gait improves markedly for several hours after removal of 40 mL of cerebrospinal fluid. Which of the following is the most appropriate next step in management?

A. Ventriculoperitoneal shunt placement
B. Donepezil
C. Acetazolamide
D. Carbidopa-levodopa trial
E. Serial therapeutic lumbar punctures indefinitely

Answer and topic summary

The answer is A. Ventriculoperitoneal shunt placement

This is normal pressure hydrocephalus, and the definitive intervention is ventriculoperitoneal shunting — a potentially reversible cause of dementia and gait failure, which is exactly why it matters that you recognize it. The classic triad is gait apraxia, urinary incontinence, and cognitive impairment (the “wobbly, wet, and wacky” mnemonic), and the magnetic, wide-based, shuffling gait is usually the FIRST symptom and the one most likely to improve after shunting. Imaging shows ventriculomegaly out of proportion to cortical atrophy, and the pressure is normal on lumbar puncture — the name is literal.

The finding that seals it is the large-volume tap test: objective gait improvement after removing 30 to 50 mL of cerebrospinal fluid is the best predictor of shunt response. That is a diagnostic maneuver, not a treatment, which is why repeating lumbar punctures indefinitely is not an answer — it is a temporizing measure that never addresses the underlying impaired cerebrospinal fluid absorption.

Donepezil is the trap, and it is the error that costs patients years: NPH is routinely misdiagnosed as Alzheimer disease and treated with a cholinesterase inhibitor. The discriminator is the sequence — in NPH gait trouble comes first and the memory problem is mild, whereas in Alzheimer disease memory loss comes first and gait stays normal until late. Acetazolamide reduces cerebrospinal fluid production in idiopathic intracranial hypertension, a different disease with high pressure and papilledema. Carbidopa-levodopa targets Parkinson disease, which shares a shuffling gait but presents with resting tremor, rigidity, and asymmetric onset — explicitly absent here.

View blueprint lesson

Smarty PANCE Content Blueprint Review:

Covered under ⇒ PANCE Blueprint Neurology ⇒ Cerebrovascular Disorders ⇒ Hydrocephalus

Sign up for the ENTIRE Blueprint Daily Email Series (1000 daily questions. . . and counting! 😀)

X

Have you tried the NEW Smarty PANCE QBANK? It's FREE with EVERY membership purchase 😀!

X